1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
REYON Pharmaceutical Co., Ltd.

REYON Pharmaceutical Co., Ltd.

102460.KS
REYON Pharmaceutical Co., Ltd.KR flagKorea Exchange
9,840.00
KRW
-150.00
- -
180.48BMarket Cap

Total Valuation

REYON Pharmaceutical Co., Ltd. carries a market capitalization of 180.48B, placing it among publicly traded companies globally. Its enterprise value stands at 399.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap180.48B
Enterprise Value399.01B

Share Statistics

REYON Pharmaceutical Co., Ltd. currently has 18.34M shares outstanding.

Shares Outstanding18.34M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.27, and the price-to-book ratio stands at 1.04.

PE RatioN/A
PS Ratio1.27
PB Ratio1.04
P/TBV Ratio0.90
P/FCF Ratio121.43
P/OCF Ratio-55.25

Enterprise Valuation

EV / Sales2.75
EV / EBITDAN/A
EV / EBITN/A
EV / FCF24.35

Financial Position

REYON Pharmaceutical Co., Ltd. maintains a current ratio of 0.52, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.58, indicating elevated leverage, while an interest coverage ratio of -2.50 demonstrates limited ability to service its debt obligations.

Current Ratio0.52
Quick Ratio0.03
Debt / Equity104.58
Debt / EBITDA-6.53
Interest Coverage-2.50

Financial Efficiency

Return on Equity (ROE)-20.64
Return on Assets (ROA)-8.60
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.85

Taxes

Income Tax3.93B
Effective Tax RateN/A

Stock Price Statistics

REYON Pharmaceutical Co., Ltd.'s stock has declined approximately -10.38251% over the past 52 weeks. The 50-day moving average sits at 10,701.40, while the 200-day moving average is 11,042.85.

Beta (5Y)N/A
52-Week Price Change-10.38251%
50-Day Moving Average10,701.40
200-Day Moving Average11,042.85
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, REYON Pharmaceutical Co., Ltd. generated 145.22B in revenue and converted that into -40.59B in net income, yielding earnings per share of -2,212.35. EBITDA reached -33.54B, while operating income came in at -33.54B.

Revenue145.22B
Gross Profit34.21B
Operating Income-33.54B
Pretax Income-36.65B
Net Income-40.59B
EBITDA-33.54B
EBIT-33.54B
Earnings Per Share (EPS)-2,212.35

Balance Sheet

REYON Pharmaceutical Co., Ltd. holds 4.35B in cash and equivalents against 219.17B in total debt, resulting in a net debt position of 213.59B. Total book value stands at 176.32B, with working capital of -71.04B providing operational flexibility.

Cash & Cash Equivalents4.35B
Total Debt219.17B
Net Debt213.59B
Equity (Book Value)176.32B
Book Value Per Share9,611.22
Working Capital-71.04B

Cash Flow

REYON Pharmaceutical Co., Ltd. produced -3.33B in operating cash flow over the past twelve months. After subtracting -4.85B in capital expenditures, free cash flow totaled -8.18B - equivalent to -446.10 per share.

Operating Cash Flow-3.33B
Capital Expenditures-4.85B
Free Cash Flow-8.18B
FCF Per Share-446.10

Margins

REYON Pharmaceutical Co., Ltd. operates with a gross margin of 23.56, reflecting its pricing power and cost economics. The operating margin of -23.09 and net profit margin of -27.95 provide insight into operational efficiency.

Gross Margin23.56
Operating Margin-23.09
Pretax Margin-25.24
Profit Margin-27.95
EBITDA Margin-23.09

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.94
FCF Yield0.82

Stock Splits

REYON Pharmaceutical Co., Ltd.'s most recent stock split took place on December 29, 2020 with a 50:51 split ratio.

Last Split Date12/29/2020
Split Ratio50:51

Scores

REYON Pharmaceutical Co., Ltd. posts an Altman Z-Score of 0.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.86